Find policies, billing codes, payers, states, and providers
HCPCS Q5142: Adalimumab-ryvk injection, 1 mg
HCPCS Level II code Q5142 denotes a 1 mg unit of adalimumab-ryvk, a biosimilar formulation of the anti-TNF biologic adalimumab administered by injection. This code matters nationally as biosimilar adoption affects drug spending, contracting, and access to biologic therapies across outpatient and ambulatory settings. Use of a biosimilar can influence payer coverage policies, step therapy pathways, and site-of-care cost considerations.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how the code is used in billing for injectable biologic therapy, common settings of service, and which payers are relevant for reimbursement and policy reviews. The publication outlines expected benchmarks and policy-relevant information, including common modifiers and billing practices (where available), as well as clinical context for adalimumab-ryvk as a biosimilar option.
This summary provides national-level context for revenue cycle, clinical, and pharmacy leaders seeking to align coding practice with payer requirements and to monitor biosimilar utilization and coverage trends. Data not available in the input is noted where specific payer policies, taxonomies, ICD-10 mappings, and related codes would normally be detailed.
Customize your policy alerts
Sign up for hcpcs Q5142 policy alerts
Get alerted when payer policies referencing Q5142 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code Q5142 indicates injection, adalimumab-ryvk biosimilar, 1 mg. This code represents a billed unit of a biosimilar form of adalimumab used for subcutaneous injection or other appropriate parenteral administration depending on clinical orders. The service type is medication administration for a biologic anti-TNF agent delivered as an injectable pharmaceutical product. The typical site of service includes outpatient infusion or injection centers, physician offices, clinics, and other ambulatory care settings where biologic injections are administered.